Your browser doesn't support javascript.
loading
Cost-benefit analysis of haemodialysis in patients with end-stage kidney disease in Abuja, Nigeria.
Agada-Amade, Yakubu Adole; Ogbuabor, Daniel Chukwuemeka; Obikeze, Eric; Eboreime, Ejemai; Onwujekwe, Obinna Emmanuel.
Afiliação
  • Agada-Amade YA; Department of Health Administration and Management, University of Nigeria, Enugu Campus, Enugu State, Nigeria Enugu, Enugu, Nigeria.
  • Ogbuabor DC; National Health Insurance Authority, Abuja, Nigeria.
  • Obikeze E; Department of Health Administration and Management, University of Nigeria, Enugu Campus, Enugu State, Nigeria Enugu, Enugu, Nigeria. daniel.ogbuabor@unn.edu.ng.
  • Eboreime E; Department of Health Systems and Policy, Sustainable Impact Resource Agency, Enugu, Nigeria. daniel.ogbuabor@unn.edu.ng.
  • Onwujekwe OE; Health Policy Research Group, Department of Pharmacology and Therapeutics, College of Medicine, University of Nigeria Enugu Campus, Enugu, Nigeria. daniel.ogbuabor@unn.edu.ng.
Health Econ Rev ; 14(1): 47, 2024 Jul 03.
Article em En | MEDLINE | ID: mdl-38958775
ABSTRACT

BACKGROUND:

Significant gaps in scholarship on the cost-benefit analysis of haemodialysis exist in low-middle-income countries, including Nigeria. The study, therefore, assessed the cost-benefit of haemodialysis compared with comprehensive conservative care (CCC) to determine if haemodialysis is socially worthwhile and justifies public funding in Nigeria.

METHODS:

The study setting is Abuja, Nigeria. The study used a mixed-method design involving primary data collection and analysis of secondary data from previous studies. We adopted an ingredient-based costing approach. The mean costs and benefits of haemodialysis were derived from previous studies. The mean costs and benefits of CCC were obtained from a primary cross-sectional survey. We estimated the benefit-cost ratios (BCR) and net benefits to determine the social value of the two interventions.

RESULTS:

The net benefit of haemodialysis (2,251.30) was positive, while that of CCC was negative (-1,197.19). The benefit-cost ratio of haemodialysis was 1.09, while that of CCC was 0.66. The probabilistic and one-way sensitivity analyses results demonstrate that haemodialysis was more cost-beneficial than CCC, and the BCRs of haemodialysis remained above one in most scenarios, unlike CCC's BCR.

CONCLUSION:

The benefit of haemodialysis outweighs its cost, making it cost-beneficial to society and justifying public funding. However, the National Health Insurance Authority requires additional studies, such as budget impact analysis, to establish the affordability of full coverage of haemodialysis.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Health Econ Rev Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Nigéria

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Health Econ Rev Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Nigéria